Daiichi Sankyo Patents Sample Clauses

Daiichi Sankyo Patents. Using counsel of its choice, AnHeart shall be responsible, at its sole expense, for preparing, filing, prosecuting, and maintaining the Daiichi Sankyo Patents that Cover the Licensed Compounds and/or Product(s), including preparing and filing requests for patent term extensions, supplemental protection certificates, pediatric exclusivity, or similar protections that extend the term of such Daiichi Sankyo Patents. AnHeart shall also be solely responsible for defending the Daiichi Sankyo Patents from any challenges to their validity or enforceability, including responding to patent office communications or office actions, oppositions, reissue or reexamination proceedings, or interferences, brought by any Third Party, whether before a patent authority or judicial body. Daiichi Sankyo shall, upon request, provide reasonable support to AnHeart in (i) preparing, filing, prosecuting, and maintaining the Daiichi Sankyo Patents and (ii) defending the Daiichi Sankyo Patents from any challenges to their validity or enforceability, including, but not limited to, providing and signing documents, or making experts available for testimony as necessary for AnHeart to fulfill its obligations under this Section 6.2.1. AnHeart will reimburse Daiichi Sankyo for reasonable 20181207 – AnHeart-DS Exclusive License out-of-pocket expenses, in accordance with AnHeart’s expense reimbursement policies, and will pay Daiichi Sankyo a rate of [**Redacted**] per day for the time expended by Daiichi Sankyo personnel for travel requested by AnHeart. If AnHeart 20181207 – AnHeart-DS Exclusive License decides that it will no longer prosecute or maintain a Daiichi Sankyo Patent, it will give Daiichi Sankyo reasonable notice of its decision, which will include sufficient time prior to the expiration or termination of all relevant deadlines for taking necessary actions to preserve the rights in such Daiichi Sankyo Patent, and will allow Daiichi Sankyo to assume control over and continue prosecuting and maintaining such Daiichi Sankyo Patent. If Daiichi Sankyo continues to prosecute and/or maintain a Daiichi Sankyo Patent after AnHeart returns responsibility to Daiichi Sankyo, such Daiichi Sankyo Patent shall [**Redacted**].

Daiichi Sankyo Patents. US or JP Apply. No. Date of filing US or JP Patent No Date of patent Date of expiration 1 * * * * * * * * * * * * * * * 2 * * * * * * * * * * * * * * * 3 * * * * * * * * * * * * * * * 4 * * * * * * * * * * * * * * * 5 * * * * * * * * * * * * * * * 6 * * * * * * * * * * * * * * * 7 * * * * * * * * * * * * * * * 8 * * * * * * * * * * * * * * * 9 * * * * * * * * * * * * * * * 10 * * * * * * * * * * * * * * * * The above list references certain Patents in the United States. Other relevant patents and patent applications (and patents issuing therefrom) throughout the world are included as Daiichi Sankyo Patents under the Agreement, but for the convenience of the Parties, are not specifically itemized above.

Daiichi Sankyo Patents. USP and its corresponding patents and patent applications* Country Appln. No. Date of filing Patent No. Date of patent Date of expiration (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) (*) *The above list references certain Patents in (*). Appendix 2. INITIAL DEVELOPMENT PLAN CLINICAL DEVELOPMENT PLAN Tesetaxel (DJ-927) CLINICAL DEVELOPMENT PLAN Tesetaxel (DJ-927) Overview: The Product is being transferred to Genta on Clinical Hold in the Territory (*).

Daiichi Sankyo Patents